Why is the FIRST study important to practice?

FAQ Library published on November 6, 2013 in Clinical Trials
Download Transcript Download Audio
Philip L. McCarthy, MD
Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York

Hello, my name is Dr. Philip McCarthy and I am the director of the Blood and Marrow Transplant program at Roswell Park Cancer Institute. I am frequently asked "Why is the FIRST study important to practice?" The FIRST study is a non-transplant eligible patient population who receive treatment upfront with lenalidomide-dex, or RD, until progression, or RD for a fixed number of cycles versus the comparator arm of melphalan-prednisone-thalidomide, also for a fixed number of cycles. The interesting question is the superiority of an RD induction versus MPT, and then the other question to be asked is should RD be given only for a fixed number of cycles or should it be given until progression, and will this impact on progression free and then ultimately on overall survival? This study was primarily conducted in the IFM, Thierry Facon is the lead study person for this MM-020, which it is also called besides the FIRST study. It is supposed to be presented at ASH 2013 and we are all very interested to see the results as we think this will inform us about length of therapy and superiority of RD versus MPT as part of induction.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Category
When do I refer a relapsed/refractory patient to a clinical trial?
FAQ Library published on February 9, 2012 in General Education, Patient Communication, Nurses & Pharmacists, Clinical Trials
What is the importance of clinical trials in patient treatment regimens?
FAQ Library published on September 16, 2010 in Clinical Trials, Nurses & Pharmacists
Related Items by Author
What are the current recommendations for providing a herpes zoster vaccine to patients with multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on September 10, 2018
Is there a benefit to providing antibiotic prophylaxis to patients being treated for multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on July 16, 2018
What is the current standard of care for follow-up monitoring of patients diagnosed with smoldering multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on June 4, 2018
What are the criteria for high-risk progression?
Philip L. McCarthy, MD
FAQ Library published on August 9, 2017
When is a patient transplant eligible?
Philip L. McCarthy, MD
FAQ Library published on June 28, 2017
What is the New R-ISS for Multiple Myeloma and Should I Be Using it?
Philip L. McCarthy, MD
FAQ Library published on November 25, 2015
How long should my patients be on maintenance therapy?
Philip L. McCarthy, MD
FAQ Library published on September 9, 2015
What are the essential considerations in a survivorship plan for multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on August 26, 2015